Please note that this product (marketed as Inlyta) was withdrawn from the Community Register of designated orphan medicinal products in July 2012 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
On 23 February 2011, orphan designation (EU/3/10/844) was granted by the European Commission to Pfizer Limited, United Kingdom, for axitinib for the treatment of renal-cell carcinoma.
|Disease / condition||
Treatment of renal-cell carcinoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.